Acute and chronic liver dysfunction is common after allogeneic bone marrow transplantation (BMT). Although toxicity, graft versus-host disease (GVHD), and viral infections are the major causes, etiologic diagnosis is difficult and often remains unknown. We conducted a prospective study to establish the role of the infection with both the hepatitis C virus (HCV) and the recently discovered hepatitis G virus (HGV) in liver dysfunction after BMT. From January 1994 to December 1995, 59 patients who had undergone an allogeneic BMT at our institution were enrolled in the study. HGV-RNA was identified in serum by nested polymerase chain reaction (PCR), and HCV was studied by the presence of second generation enzyme-linked immunosorbent assay (ELISA)-antibodies and HCV-RNA by nested PCR. HGV-RNA was detected in 25 patients (42%) (before BMT in 18 and after BMT in 7). HCV-RNA was present in 12 patients (20%) (before BMT in 11 and after BMT in one). The presence of HCV-RNA and HGV-RNA was clearly associated with a previous history of blood transfusions. No significant association was found between viral infection and acute liver toxicity. Some degree of liver dysfunction was present 6 months after BMT in 25 of 40 evaluable patients (62%). Long-term liver dysfunction was more common among patients infected with HCV alone (3 of 4) or with both HCV and HGV (3 of 3) than in those infected with either HGV alone (eight of 13) or with no virus infection (10 of 20). We found a high prevalence of HGV infection in our BMT population. However, no role for HGV in liver disease could be established in this study, and the relationship between HGV infection and liver dysfunction requires further clarification.

LIVER DYSFUNCTION is an important cause of morbidity and mortality after allogeneic bone marrow transplantation.1 Among the causes of liver damage are acute and chronic graft-versus-host disease (GVHD), toxic liver cell damage due to chemotherapy, including venoocclusive liver disease (VOD), and viral infections2-4 (hepatitis C virus [HCV]).

Two hepatitis-associated viruses termed GB virus C (GBV-C) or hepatitis G virus (HGV)6 have recently been isolated. Both viruses share a 95% nucleotide homology demonstrating that GBV-C and HGV are different isolates of the same virus. This new agent is parenterally transmitted,7-9 its prevalence is from 1% to 2% in voluntary donors from the United States, and it is more frequent than HCV in the general population.10 Although there has been rapid increase in the molecular and epidemiologic knowledge of HGV, its clinical relevance remains largely unresolved. Patients who undergo bone marrow transplantation (BMT) are exposed to a large number of blood transfusions and suffer from a profound immunosuppression. Accordingly, the hypothesis that this new agent may infect this patient population and play a role in post-BMT liver abnormalities seems plausible. Thus, the aim of this study was to analyze the prevalence of both HCV and HGV infections, as well as their influence on liver function abnormalities after allogeneic BMT.

Patients

We prospectively studied 59 patients who had undergone an allogeneic BMT from January 1994 to December 1995. The clinical and technical characteristics are shown in Table 1. The median follow-up period for surviving patients has been 502 days (range, 184 to 822 days). The aim of the study was to determine the possible role of hepatitis C and G viruses in both acute and chronic liver dysfunction after allogeneic BMT. This study was approved by the Ethics Committees of our institutions.

Table 1.

Clinical Characteristics

 
Median age (range) 32 (17-49) 
Underlying disease and status 
Acute leukemia 31 
First complete remission 18 
Second complete remission 
Refractory disease 
Early untreated relapse 
Chronic myeloid leukemia 19 
First chronic phase 14 
Advanced disease 
Severe aplastic anemia 
Myelodysplastic syndrome 
Multiple myeloma 
Donors 
HLA identical sibling 56 
Unrelated (A, B, DRB1 identical) 
One mismatched family donor 
Second BMT 
Conditioning regimen 
BuCy2 37 
CyTBI 15 
CyTLI 
BuCyVP16 
Cy-ATG 
CyTBI Thiotepa 
VOD 9/59 (15%) 
Fatal VOD 2/59 (3,3%) 
Acute grade II-IV GVHD 21/56 (37,5%) 
Chronic GVHD 14/43 (32,5%) 
Status: alive/dead 40/19 
Causes of death 
Acute GVHD infection 
Relapse 
VOD 
CMV interstitial pneumonitis 
Multiorgan failure and sepsis 
Hemorrhage 
 
Median age (range) 32 (17-49) 
Underlying disease and status 
Acute leukemia 31 
First complete remission 18 
Second complete remission 
Refractory disease 
Early untreated relapse 
Chronic myeloid leukemia 19 
First chronic phase 14 
Advanced disease 
Severe aplastic anemia 
Myelodysplastic syndrome 
Multiple myeloma 
Donors 
HLA identical sibling 56 
Unrelated (A, B, DRB1 identical) 
One mismatched family donor 
Second BMT 
Conditioning regimen 
BuCy2 37 
CyTBI 15 
CyTLI 
BuCyVP16 
Cy-ATG 
CyTBI Thiotepa 
VOD 9/59 (15%) 
Fatal VOD 2/59 (3,3%) 
Acute grade II-IV GVHD 21/56 (37,5%) 
Chronic GVHD 14/43 (32,5%) 
Status: alive/dead 40/19 
Causes of death 
Acute GVHD infection 
Relapse 
VOD 
CMV interstitial pneumonitis 
Multiorgan failure and sepsis 
Hemorrhage 

Abbreviations: Bu, busulfan; Cy, cyclophosphamide; TLI, total lymphoid irradiation; VOD, venoocclusive disease of the liver; GVHD, graft-versus-host disease; CMV, cytomegalovirus.

Transplantation Procedure

The methods used in allogeneic BMT have previously been reported.11 All of the patients were hospitalized in single rooms ventilated through high-efficiency particular air (HEPA) filtration systems. Trimethoprim/sulfamethoxazole was administered to all patients from day −7 to day −1 and given again twice per week during engraftment for 6 months after transplant. All patients received intravenous parenteral nutrition, which started on day +1 and continued until oral tolerance was achieved. Broad spectrum antibiotics and amphotericin-B were used as previously described.11,12 In recipients seropositive for cytomegalovirus (CMV) or in those whose donors were seropositive for CMV, high-dose acyclovir (500 mg/m2/intravenously [IV]/8 hours) was administered from day −5 to day +30. None of the patients received growth factors or intravenous gammaglobulin.

Busulfan (16 mg/kg)-cyclophosphamide (120 mg/kg) (BuCy2) and Cy (120 mg/kg) with fractioned total body irradiation (TBI) (1,200 cGy divided in six doses administered on days −3, −2, and −1) (CyTBI) were the conditioning regimens more commonly employed. Irradiation was delivered by a 60Co irradiation source at a dose rate of 4 to 7 cGy/min. Patients with severe aplastic anaemia were treated with either Cy and total lymphoid irradiation or anti-thymocyte globulin (ATG). VP-16 (30 mg/kg) was added to BuCy2 in two patients and the patient with multiple myeloma received TBI (900 Gy), cyclophosphamide (120 mg/kg), and thiotepa (500 mg/m2).

All patients received non-T–cell-depleted bone marrows, which were infused on day 0. A median of 3.4 × 108 nucleated bone marrow cells per kilogram of receiving body weight was infused (range, 1.8 to 5.2). Cyclosporine (CsA) and a short course of methotrexate according to the Seattle protocol for GVHD prophylaxis13 was given in all cases. After day +100, the CsA dose was decreased by 5% per week and discontinued 6 months after transplantation in patients with no evidence of GVHD. Acute GVHD was classified according to Deeg's grading14 and chronic GVHD was graded as either limited or extensive according to classical criteria.12.

Early liver dysfunction was defined as either an increase in alanine aminotransferase (ALT) levels above the normal value or a bilirubin level greater than 2 mg/dL. Venoocclusive disease (VOD) was diagnosed according to clinical findings when the three major criteria (weight gain, jaundice, and hepatomegaly) were present.15 Patients without acute GVHD, VOD criteria, or other identified causes of liver dysfunction were classified as having acute liver toxicity related to the preparatory regimen and the transplantation procedure. For patients who survived longer than 180 days after BMT, the presence of liver dysfunction was defined as an increase in ALT levels above the normal value that persisted for more than 3 months.

Viral Markers

Hepatitis-B virus surface antigen (HBsAg), as well as antibodies against HBsAg (anti-HBs) and hepatitis B virus core antigen (Anti-HBc), were tested by commercially available enzyme immunoassays (Abbott, North Chicago, IL).

Antibodies against HCV (anti-HCV) were detected by first- and second-generation enzyme-linked immunosorbent assay (ELISA) tests (Ortho, Raritan, NJ). Serum HCV-RNA was determined by reverse transcription and nested polymerase chain reaction (PCR) (RT-PCR), using primers from the highly conserved 5′noncoding region of the HCV genome.16 HCV-RNA quantitation was performed using the Amplicor HCV Monitor test kit (Roche Diagnostic System, Brandiburg, NJ). HCV-RNA genotyping was performed as described by Davidson et al.17 

For the detection of HGV RNA, total RNA from serum samples was isolated as described.18 The total RNA thus obtained was amplified by RT-PCR, using specific primers of the putative helicase/NS3 gene designed according to the HGV sequence reported by Simons et al,5 which amplifies a 272-bp fragment of the HGV genome, as well as primers from the 5′ noncoding region, according to the sequence reported by Leary et al,19 which amplifies a 320-bp fragment. The antisense oligonucleotides AMS3 (NS3 region) and S1 (5′noncoding region) were used to prime cDNA synthesis of the genomic HGV strand. After an RNA denaturation step (5 minutes at 95°C), AMV-RT was added, and reverse transcription was performed at 42°C for 30 minutes. Finally, avian myeloblastosis virus reverse-transcriptase (AMV-RT) was inactivated by heating at 95°C for 15 minutes.

For NS3 amplification, the first 35-cycle PCR rounds were performed using the AMS1 primer at 94°C for 1.5 minutes, 55°C for 1.5 minutes, and 72°C for 1 minute, with a final extension step at 72°C for 7 minutes. The second PCR round was performed under the same conditions, with 10% of the first PCR product, using the AMS2 and AMS4 primers. For the 5′noncoding region amplification, the S1 primer was used in the first PCR. The conditions for the first 35 PCR cycles were 95°C, 1 minute, 50°C, 1 minute, and 72°C, 1 minute. For the second PCR, 10% of the first PCR product was amplified using the same conditions as for the first PCR round and the primers S2 y A2 (sequence and position of the primers used is shown in Table 2).

Table 2.

Sequence and Nucleotide Position of the Primers Used in HGV RNA Amplification

5′ Noncoding Region
Nucleotide SequencePosition
Outer primers S1 CACTGGGTGCAAGCCCCAGAA 13-33 
 A1 CACTGGTCCTTGTCAACTCGC 358-378 
Inner primers S2 CGACGCCTACTGAAGTAGACG 36-56 
 A2 GTACGCCTATTGGTCAAGAGA 336-356 
  NS3/Helicase Region 
    
Outer primers AMS1 GCTCGCCTATGACTCAGCATC 4194-4214 
 AMS3 GTCACCTCAACGACCTCCTCC 4504-4524 
Inner primers AMS2 GAGACAAAGCTGGACGTTGGT 4226-4246 
 AMS4 CAACCCACAGTCGGTGACAGA 4478-4498 
5′ Noncoding Region
Nucleotide SequencePosition
Outer primers S1 CACTGGGTGCAAGCCCCAGAA 13-33 
 A1 CACTGGTCCTTGTCAACTCGC 358-378 
Inner primers S2 CGACGCCTACTGAAGTAGACG 36-56 
 A2 GTACGCCTATTGGTCAAGAGA 336-356 
  NS3/Helicase Region 
    
Outer primers AMS1 GCTCGCCTATGACTCAGCATC 4194-4214 
 AMS3 GTCACCTCAACGACCTCCTCC 4504-4524 
Inner primers AMS2 GAGACAAAGCTGGACGTTGGT 4226-4246 
 AMS4 CAACCCACAGTCGGTGACAGA 4478-4498 

Tests for HCV (serology and HCV-RNA detection) and HGV were performed on the day of admission for BMT, as well as on days +30, +180, and +360 in all enrolled patients.

A liver biopsy was scheduled for all patients with persistent liver dysfunction or without a clear clinical diagnosis. A total of 24 liver biopsies was obtained from 23 patients. All histologic samples were reviewed by two independent pathologists.

Statistical Analysis

Values are expressed as either medians and intervals or percentages. For qualitative variables, both the χ2 test and the Fischer exact test were used, while the Student's t-test was used for quantitative variables. All of the analyses were performed through SPSS v 6.0 (Chicago, IL) statistical packages on a Macintosh computer.

Prevalence of HGV, HCV, and Hepatitis B Virus (HBV) Infection

Among the 59 patients enrolled in this study, HGV-RNA alone, HCV-RNA alone, and both viral genomes were detected in 12 (20%), 5 (8.5%), and 6 patients (10%), respectively, before BMT. Nine of the 11 patients with HCV-RNA had anti-HCV antibodies. The HCV genotype was 1b in all cases. HBsAg was not found in any patient, although 17 had antibodies against HBV (anti-HBs or anti-HBc).

All patients (n = 23) infected with hepatitis viruses before BMT had undergone pre-BMT blood transfusions, while this occurred in only 15 of the 36 (41.6%) patients with no evidence of viral infection (P < .05). Furthermore, infected patients were exposed to a significantly higher number of donors than noninfected patients (95.7 ± 80.6 v 27.5 ± 39.4, P < .0001).

Five of the 11 patients with HCV-RNA had received transfusions before the introduction of anti-HCV screening, 2 of 11 had been transfused with blood products screened by first-generation ELISA for anti-HCV, and 4 of 11 had received blood tested by second-generation tests.

Abnormally high ALT levels before BMT were more common in patients infected with both viruses (5 of 6, 83%), followed by those infected with HCV alone (2 of 5, 40%), and HGV alone (3 of 12, 25%). In contrast, only 4 of 36 (11%) of the patients not infected with any of the hepatotropic viruses had abnormal baseline ALT levels. However, no statistical differences were observed in ALT levels among the four groups of patients (Table 3).

Table 3.

Clinical Characteristics of Patients Infected With HGV or HCV Before BMT and Analysis of Early Liver Dysfunction After BMT

NoneHGV RNA+HCV RNA+HCV and HGV RNA+
(n = 36)(n = 12)(n = 5)(n = 6)
History of transfusion 15/36 12/12 5/5 6/6 
Exposed donors 10 (0-33) 82 (3-236) 112 (49-164) 84 (12-344) 
Underlying disease 
CML 18 AL 10 AL 5 AL 5 
AL 11 SAA 1  CML 1 
MDS MM 1  
SAA    
Stage at BMT 
Active disease3-150 5/33 (15%) 1/12 (8%) 2/5 (40%) 4/6 (66%) 
Second BMT 
Abnormal ALT before BMT 4 (11%) 3 (25%) 2 (40%) 5 (83%) 
Maximum ALT levels in the first 100 days after BMT 67 (24-2925) 111 (41-900) 87 (10-271) 290 (113-490) 
Day of maximum ALT 14 (0-30) 21 (2-30) 5 (1-20) 7 (3-18) 
Type of early liver dysfunction 
No liver toxicity  
Toxicity 22 
Acute GVHD 
VOD (fatal VOD) 3 (0) 1 (0) 1 (0) 4 (2) 
NoneHGV RNA+HCV RNA+HCV and HGV RNA+
(n = 36)(n = 12)(n = 5)(n = 6)
History of transfusion 15/36 12/12 5/5 6/6 
Exposed donors 10 (0-33) 82 (3-236) 112 (49-164) 84 (12-344) 
Underlying disease 
CML 18 AL 10 AL 5 AL 5 
AL 11 SAA 1  CML 1 
MDS MM 1  
SAA    
Stage at BMT 
Active disease3-150 5/33 (15%) 1/12 (8%) 2/5 (40%) 4/6 (66%) 
Second BMT 
Abnormal ALT before BMT 4 (11%) 3 (25%) 2 (40%) 5 (83%) 
Maximum ALT levels in the first 100 days after BMT 67 (24-2925) 111 (41-900) 87 (10-271) 290 (113-490) 
Day of maximum ALT 14 (0-30) 21 (2-30) 5 (1-20) 7 (3-18) 
Type of early liver dysfunction 
No liver toxicity  
Toxicity 22 
Acute GVHD 
VOD (fatal VOD) 3 (0) 1 (0) 1 (0) 4 (2) 

Abbreviations: CML, chronic myeloid leukemia; AL, acute leukemia; SAA, severe aplastic anemia; MDS, myelodysplastic syndrome; MM, multiple myeloma; GVHD, graft-versus-host disease; VOD, venoocclusive disease of the liver.

F3-150

Active disease: patients with acute leukemia or CML transplanted in situation other than remission or first chronic phase.

Fourteen of the 18 patients with HGV-RNA had received blood transfusions screened by second-generation tests for HCV determination.

Of the 36 patients negative for both HCV-RNA and HGV RNA before BMT, seven became positive for HGV RNA and one for HCV-RNA after BMT (the latter patient never developed antibodies or liver dysfunction).

Analysis of Liver Dysfunction During the Early Posttransplant Period (from the start of cytoreductive therapy to day 100)

During the 100 days after BMT, ALT levels remained normal in only nine patients receiving chemotherapy or other drugs, irrespective of the presence of either new or past hepatitis virus infection (data not shown). Nine patients developed VOD after BMT, and two of them died. Table 3 shows the pre-BMT clinical features of early liver dysfunction in all of our patients, divided according to virus status. Maximum ALT levels were significantly higher in those patients infected with both types of viruses than in the other groups (P = .01). VOD was also significantly more common in the former group of patients (P = .05). However, four of these six patients were transplanted while having an active hematologic disease; the two remaining cases (chronic myeloid leukemia [CML] and acute lymphoblastic leukemia [ALL]) had undergone a second BMT. At that time, four cases had elevated ALT levels, a very well-known risk factor for VOD. Five of the 59 patients (8.5%) died of hepatic disease in this early period. Two patients infected with HCV and HGV died of severe VOD (both of them had been transplanted while in refractory relapse with high ALT levels of 240 IU and 92 IU and in one case, a second BMT); three other patients died of therapy-resistant grade IV hepatic GHVD.

During this period, liver samples were obtained from 9 patients (by transjugular biopsy in 5 cases, percutaneous liver biopsy in 3, and autopsy in 1). The histologic diagnosis was acute GVHD and VOD in 6 and 3 cases, respectively.

Analysis of Liver Dysfunction After Day 100

Characteristics of the patients infected with HGV alone.Thirteen of the 19 patients infected with HGV were evaluable for liver function after day 100 (Table 4). Six patients were not evaluable for various reasons: fatal grade IV-acute GVHD (3 patients), multiorgan failure and sepsis (1 patient), and early relapse (2 patients). With a median follow-up of 536 days after BMT (range, 347 to 942 days), 8 of these 13 patients had an increase in ALT levels after BMT. In 4 cases, the diagnosis was chronic GVHD of the liver (proven by liver biopsy in all cases). The other 4 patients were diagnosed by liver biopsy of iron overload (two patients), steatohepatitis (one patient) and undetermined (one patient, not biopsied). Serum HGV-RNA remained detectable in all patients.

Table 4.

Analysis of Liver Dysfunction After Day 100 in 40 Evaluable Patients According to HCV and HGV Virus Status

NoneHGV RNA+HCV RNA+HCV RNA and HGV RNA+
(n = 20)(n = 13)(n = 4)(n = 3)
Median follow-up (d) 532 (278-929) 536 (347-992) 662 (552-823) 460 (283-921) 
Underlying disease 
CML 11 AL 11 AL 3 AL 2 
AL SAA 1 CML 1 CML 1 
MDS CML 1   
SAA    
Liver dysfunction 10/20 8/13 3/4 3/3 
Type of liver dysfunction 
Chronic GVHD  
Iron overload 
CAH    
Acute viral hepatitis    
Steatohepatitis    
Undetermined  
ALT levels at last clinical visit 
(Normal/abnormal 16/4 11/2 1/3 0/3 
% patients with abnormal levels) 20% 15% 75% 100% 
NoneHGV RNA+HCV RNA+HCV RNA and HGV RNA+
(n = 20)(n = 13)(n = 4)(n = 3)
Median follow-up (d) 532 (278-929) 536 (347-992) 662 (552-823) 460 (283-921) 
Underlying disease 
CML 11 AL 11 AL 3 AL 2 
AL SAA 1 CML 1 CML 1 
MDS CML 1   
SAA    
Liver dysfunction 10/20 8/13 3/4 3/3 
Type of liver dysfunction 
Chronic GVHD  
Iron overload 
CAH    
Acute viral hepatitis    
Steatohepatitis    
Undetermined  
ALT levels at last clinical visit 
(Normal/abnormal 16/4 11/2 1/3 0/3 
% patients with abnormal levels) 20% 15% 75% 100% 

Abbreviation: CAH, chronic active hepatitis.

Characteristics of the patients infected with HCV alone.Of the six patients infected with HCV alone, two died due to early relapse. Three of the four remaining patients had consistently abnormal ALT values and detectable HCV-RNA. Two patients exhibited a chronic active hepatitis and a moderate cytolysis with iron overload, as shown by liver biopsy. In the other patient, ALT levels reached normal values after venesections. When comparing baseline with last serum samples, the concentration of HCV RNA increased in patients infected with HCV alone (baseline 0.24 × 106 ± 0.4 × 106 genome copies/mL, final 0.37 × 106 ± 0.34 × 106 genome copies/mL) or in those infected with HGV and HCV simultaneously (baseline 0.27 × 106 ± 0.34 × 106 genome copies/mL, final 0.29 × 106 ± 0.39 × 106 genome copies/mL); the differences, however, were not stastistically significant. Genotype 1b remained detectable in all HCV-infected patients throughout the study.

Characteristics of the patients infected with both HCV and HGV.Three of the six patients infected with both types of viruses before BMT died of BMT-related complications (VOD, two patients; acute GVHD, one patient). Another patient relapsed from AML (day +215) and developed a histologically proven acute hepatitis on day +172 with an increase in HCV-RNA concentration (0.049 × 105v 0.065 × 106). The other two patients developed liver function abnormalities after day 100. In one of these patients, who relapsed from CML after the second allogeneic BMT, HGV disappeared from the serum after treatment with interferon (IFN)-α 2a for CML relapse.20 The other surviving patient had a histologically proven chronic GVHD, but the presence of cytolysis and portal infiltration was also noted.

Characteristics of the 28 patients with neither HCV nor HGV virus infection.Eight of 28 patients were not evaluable for liver dysfunction after day 100 due to acute GVHD (n = 4), early relapse (n = 2), fatal hemorrhage (n = 1), and loss to follow up (one patient). Ten of the 20 evaluable cases had developed some type of liver function abnormality after day 100. The diagnosis was chronic GVHD in 6 cases (proven by liver biopsy in 5 cases), iron overload in 3 cases (proven by liver biopsy in 2 cases), and undetermined in 1 case.

ALT levels at the end of follow-up.Table 4 displays the percentage of patients with normal ALT levels in the last clinical evaluation according to their hepatitis virus status.

HGV and HCV infection and engraftment.There were no statistical differences in terms of neutrophil (>500 and >1,000/μL) or platelet (>20,000/μL >100,000/μL) recovery and HCV and HGV status (data not shown).

In the present study, we have found a high incidence (42%) of HGV infection in a group of patients who had undergone BMT. This percentage is higher than that reported in other risk populations, such as hemophiliacs (18%),6 multitransfused patients (18%),6 or patients on maintenance hemodialysis (3.1%)21; however, it is similar to that communicated by Neilson et al22 for long-term survivors of hematologic malignancy (47%). All of the patients who were positive for HGV-RNA before BMT had been transfused before transplant. Seven patients acquired the virus after BMT, which represented 19% of the previously noninfected patients. These data support the hypothesis that HGV is transmitted by blood. On the other hand, 25 of the 29 patients had received blood donations tested by second generation ELISA test for anti-HCV antibodies. This finding shows that anti-HCV is not useful as a surrogate marker of HGV infection.

A high prevalence of HCV infection among this group of patients (20%) was observed. This prevalence is related to the period when the patients were transfused, as 7 patients received multiple transfusions before adequate screening tests for HCV infection were available. However, 4 infected patients had received blood screened by second generation ELISA assays before BMT, and they probably became infected by blood anti-HCV negative, but with HCV-RNA. The fact that 3 of our patients had serum HCV-RNA, but no anti-HCV, suggests that testing for anti-HCV alone may not be useful for the diagnosis of HCV infection in BMT patients, as previously reported.23 In this study, 13 evaluable patients were infected with HGV alone so that the possible effects of this infection on BMT could be studied. Among these 13 patients, 5 had consistently normal ALT levels, which argues against a possible pathogenic role of HGV in chronic liver disease. Although fulminant hepatitis has been associated with HGV,24 we did not find any case of acute or fulminant hepatitis in our patients. Because posttransplant immunosuppression increased viral titers of HCV, a similar effect would be expected with respect to HGV; if so, the development of liver disease due to this agent would be more likely, although that was not the case in our patients. All of these results reinforce the argument that HGV might not be a hepatitis virus at all, as has been proposed recently by other investigators.10,25,26 

Hepatitis G virus has been linked to aplastic anemia.27,28 We examined the effect of HGV infection on engraftment parameters, although no differences were found in terms of neutrophil or platelet recovery among patients with or without HGV infection. Differences were not even noted in the early or late outcome of BMT between patients with or without HGV infection. All of these results demonstrate that although HGV infection is frequent among BMT patients, no clear hematologic or hepatic pathogenicity due to this agent was evident. Nevertheless, long-term follow-up of HGV-infected patients should be performed to confirm the benign prognosis of this infection.

In contrast to HGV infection, patients with HCV had abnormal ALT levels and a histologically proven chronic hepatitis. Therefore, the prognosis of HCV-infected patients would be different from that of HGV-infected patients. The latter patients may thus require antiviral therapy after BMT.

With respect to the HGV and HCV-coinfected patients, the behavior was similar to those who had only HCV infection. This finding demonstrates that HCV has a predominant pathogenic role in patients infected with both viruses.

Finally, the frequency of abnormal ALT levels at the last visit in patients with neither HGV nor HCV infection, was statistically lower (20%) than that found in patients with hepatitis C or hepatitis C and G virus infection (75% to 100%), although it was similar to that in patients with HGV infection alone. These results show again that HGV has no role in causing liver damage in BMT patients.

Supported by Grants No. FIS 93/0522 from the “Fondo de Investigaciones Sanitarias de la Seguridad Social,” National Institute of Health of Spain, and the Fundación para el Estudio de las Hepatitis Virales (Madrid, Spain).

Presented at the 38th Annual Meeting of the American Society of Hematology, Orlando, FL, December, 1996.

E.R-I. and J-F.T. contributed equally to this work.

Address reprint requests to José-Francisco Tomás MD, Department of Hematology, Hospital Universitario La Princesa, c/Diego de León 62, 28006 Madrid, Spain.

1
Shuhart MC, McDonald GB: Gastrointestinal and hepatic complications, in Forman SJ, Blume KG, Thomas ED (eds): Bone Marrow Transplantation. Cambridge MA, Blackwell, 1994, p 454
2
Ljungman
P
Johansson
N
Galumann
H
Lönnqvist
B
Ringden
O
Sparrelid
E
Sönnerborg
A
Winiarski
J
Gahrton
G
Long-term effects of hepatitis C virus infection in allogeneic bone marrow transplant recipients.
Blood
86
1995
1614
3
Fujii
Y
Kahu
K
Tanaka
M
Kaneko
T
Matumoto
N
Shinohara
K
Hepatitis C virus infection and liver disease after allogeneic bone marrow transplantation.
Bone Marrow Transplant
13
1994
523
4
Tomás JF, Pinilla I, Gómez-Garcı́a de Soria, Garcı́a-Buey ML, Figuera A, Fernández-Rañada JM: Long-term liver dysfunction after allogeneic bone marrow transplantation: Importance of hepatitis C virus infection and iron overload. Blood 86:865a, 1995 (abstr, suppl 1)
5
Simons
JN
Leary
TP
Dawson
GJ
Pilot-Matias
TJ
Muerhoff
AS
Schaluder
GG
Desai
SM
Mushahwar
IK
Isolation of novel virus-like sequences associated with human hepatitis.
Nature Med
1
1995
564
6
Linnen
J
Wages
J
Zhang-Keck
Z-Y
Fry
KE
Krawczynski
KZ
Alter
H
Koonin
E
Gallager
M
Alter
M
Hadziyannis
S
Karayiannis
P
Fung
K
Nakatsugi
Y
Shih
JWK
Young
L
Piatak
Jr M
Hoover
C
Fernández
J
Chen
S
Zou
JC
Morris
T
Hyams
KC
Imsay
S
Lifson
JD
Hess
G
Foung
SKH
Thomas
H
Bradley
D
Margolis
H
Kim
JP
Molecular cloning and disease association of hepatitis G virus: A transfusion-transmissible agent.
Science
271
1996
505
7
Aikawa
T
Sugai
Y
Okamoto
H
Hepatitis G infection in drug abusers with chronic hepatitis C.
N Engl J Med
334
1996
195
8
Masuko
K
Mitsiu
T
Iwano
K
Yamazaki
C
Okuda
K
Meguro
T
Murayama
N
Inoue
T
Tsuda
F
Okamoto
H
Miyakawa
Y
Mayumi
M
Infection with hepatitis GB virus C in patients on maintenance hemodialysis.
N Engl J Med
334
1996
1485
9
Wang
JT
Tsai
FC
Lee
C-Z
Chen
PJ
Sheu
JC
Wang
TH
Chen
DS
A prospective study of transfusion-transmitted GB virus C infection: Similar frequency but different clinical presentation compared with hepatitis C virus.
Blood
88
1996
1881
10
Alter
HJ
The cloning and clinical implications of HGV and HGBV-C.
N Engl J Med
334
1996
1536
11
Tomás JF, Gómez-Garcı́a de Soria V, López-Lorenzo JL, Arranz R, Figuera A, Cámara R, Alegre A, Fernández-Rañada JM: Autologous or allogeneic bone marrow transplantation for acute myeloblastic leukemia in second complete remission: Importance of duration of first complete remission in final outcome. Bone Marrow Transplant 17:979, 1996
12
Sullivan
KM
Shulman
HM
Storb
R
Weiden
PL
Witherspoon
RP
McDonald
GB
Thomas
ED
Chronic graft-versus-host disease in fifty-two patients: Adverse natural course and successful treatment with combination immunosupression.
Blood
57
1981
267
13
Storb
R
Deeg
HJ
Withehead
J
Appelbaum
F
Beatty
P
Bensinger
W
Clift
RA
Buckner
CD
Thomas
ED
Methotrexate and cyclosporine versus cyclosporine alone for prophylaxis of acute graft-versus-host disease after marrow transplantation for leukemia.
N Engl J Med
314
1986
729
14
Deeg
HJ
Storb
R
Acute graft-versus-host disease: Clinical manifestations, prophylaxis, and treatment.
J Natl Clin Invest
76
1986
1325
15
McDonald
GB
Sharma
P
Matthews
DE
Shulman
HM
Thomas
ED
Venocclusive disease of the liver after bone marrow transplantation: Diagnosis, incidence, and predisposing factors.
Hepatology
4
1984
116
16
Castillo
I
Bartolomé
J
Navas
S
Gonzalez
S
Herrero
M
Carreño
V
Virological and biochemical long-term follow-up of patients with chronic hepatitis C treated with interferon.
Hepatology
19
1994
1342
17
Davidson
F
Simmonds
P
Ferguson
JC
Jarvis
LM
Dow
BC
Follett
EAC
Seed
CRG
Krusius
T
Lin
C
Medgyesi
GA
Kiyokawa
H
Olim
G
Duraisamy
G
Cuypers
T
Saeed
AA
Teo
D
Conradie
J
Kew
MC
Lin
M
Nuchaprayoon
C
Ndimbie
OK
Yap
PL
Survey of major genotypes and subtypes of hepatitis C virus using RFLP of sequences amplified from the 5′non-coding region.
J Gen Virol
76
1995
1197
18
Chomzynski
P
Sacchi
N
Single-step method of RNA isolation byacid guanidinium thiocyanate-phenol-chloroform extraction.
Anal Biochem
162
1987
156
19
Leary
TP
Muerhoff
AS
Simons
JN
Pilot-matias TJ
Erker
JC
Chalmers
ML
Schlauder
GG
Dawson
GJ
Desai
SM
Mushahwar
IK
Sequence and genomic organization of GBV-C: A novel member of the Flaviviridae associated with human non-A-E hepatitis.
J Med Virol
48
1996
60
20
Tomás
JF
Bartolomé
J
Carreño
V
Hepatitis GB virus C.
N Engl J Med
335
1996
1393
21
Masuko
K
Mitsiu
T
Iwano
K
Yamazaki
C
Okuda
K
Meguro
T
Murayama
N
Inoue
T
Tsuda
F
Okamoto
H
Miyakawa
Y
Mayumi
M
Infection with hepatitis GB virus C in patients on maintenance hemodialysis.
N Engl J Med
334
1996
1485
22
Neilson
J
Harrison
P
Milligan
DW
Skidmore
SJ
Collingham
KE
Hepatitis G virus in lomg-term survivors of haematological malignancy.
Lancet
347
1996
1632
23
Locasciulli
A
Bacigalupo
A
VanLint
MT
Cavalletto
D
Pontisso
P
Testa
M
Masera
G
Shulman
HM
Portmann
B
Alberti
A
Hepatitis C virus infection and liver failure in patients undergoing allogeneic bone marrow transplantation.
Bone Marrow Transplant
16
1995
407
24
Yoshiba
M
Okamoto
H
Mishiro
S
Detection of the GBV-C hepatitis virus genome in serum from patients with fulminant hepatitis of unknown etiology.
Lancet
346
1995
1131
25
Alter
MJ
Gallagher
M
Morris
TT
Moyer
LA
Meeks
EL
Krawczynski
K
Kim
JP
Margolis
HS
Acute non-A-E hepatitis in the United States and the role of hepatitis G virus infection.
N Engl J Med
336
1997
741
26
Alter
HJ
Nakatsuji
Y
Melpolder
J
Wages
J
Wesley
R
Shih
JWK
Kim
JP
The incidence of transfusion-associated hepatitis G virus infection and its relation to liver disease.
N Engl J Med
336
1997
747
27
Zaidi
Y
Chapman
CS
Myint
S
Aplastic anaemia after HGV infection.
Lancet
348
1996
472
28
Byrnes
JJ
Banks
AT
Piatack
M
Kim
JP
Hepatitis G-associated aplastic anaemia.
Lancet
348
1996
472
Sign in via your Institution